Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Revenue (2016 - 2025)

Cytosorbents (CTSO) has disclosed Revenue for 14 consecutive years, with $9.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue rose 10.12% year-over-year to $9.5 million, compared with a TTM value of $37.0 million through Sep 2025, up 2.25%, and an annual FY2024 reading of $35.6 million, up 14.51% over the prior year.
  • Revenue was $9.5 million for Q3 2025 at Cytosorbents, down from $9.6 million in the prior quarter.
  • Across five years, Revenue topped out at $12.0 million in Q2 2021 and bottomed at $8.1 million in Q3 2022.
  • Average Revenue over 5 years is $9.4 million, with a median of $9.4 million recorded in 2022.
  • The sharpest move saw Revenue increased 22.76% in 2021, then dropped 29.35% in 2022.
  • Year by year, Revenue stood at $10.8 million in 2021, then fell by 12.91% to $9.4 million in 2022, then dropped by 7.69% to $8.7 million in 2023, then increased by 5.56% to $9.2 million in 2024, then rose by 3.66% to $9.5 million in 2025.
  • Business Quant data shows Revenue for CTSO at $9.5 million in Q3 2025, $9.6 million in Q2 2025, and $8.7 million in Q1 2025.